Navigation Links
Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
Date:4/15/2008

ng statements. Such forward-looking statements include statements about the ability of Iomai's adjuvant patches to provide protective immune responses with one or two doses of H5N1 influenza vaccine; the significance of the results described in this press release to government health officials in addressing an outbreak of pandemic influenza; that the clinical trial data from the new clinical trial will be sufficient to proceed next with a pivotal Phase 3 clinical trial; that the characteristics of Iomai's adjuvant patch described in this press release would make the product ideal for stockpile and rapid distribution; the anticipated reimbursement for the costs associated with further testing of the adjuvant the patch and the potential future funding authorized by HHS. Applicable risks and uncertainties include, among others, that future clinical trials may not replicate results seen in the trial described in this press release; that the U.S. Food and Drug Administration or other regulatory authorities may not concur with Iomai's analysis of the trial results described in this press release; that Iomai may not be able to enroll sufficient numbers of subjects in future clinical trials; that Iomai may be unable to obtain the regulatory approvals or financing necessary to conduct additional clinical trials, or to develop the product to a point where the adjuvant patch can be sold to the government for stockpiling for its pandemic influenza program; that competitors may develop products that are safer, more effective, or more convenient to use; future clinical results may not support regulatory approval to commercialize Iomai's adjuvant patch for pandemic influenza applications, which will depend on the outcome of additional clinical trials and analysis by regulatory authorities of data Iomai submits; that Iomai may not meet its contractual milestones in order to fully perform under the contract and thereby receive complete reimbursement from HHS; that Congress will not
'/>"/>
SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
5. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern ... Both established medical-device providers as well as new medical-device ... region, while simultaneously looking at ways to reduce the ... Using distributors is one of the effective means to ... devices distribution market in Eastern European and provides profiles ...
(Date:9/30/2014)... 2014 The report based on ... Share, Growth and Forecast, 2007 - 2017," elaborated by ... 20.8 billion in 2012 and is further expected to ... CAGR of 7.3% from 2012 to 2017. ... purposes, especially to prevent chronic diseases that may occur ...
(Date:9/30/2014)... In a recent study it ... of the Eldor spinal needle 25G, 103 mm appeared ... point spinal needles of the same gauge and length ... is an excellent type of regional anesthesia for many ... It is estimated that 100 million patients ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... 2011 Actavis Group, an international generic pharmaceuticals company, ... US Food & Drug Administration to market Valacyclovir Hydrochloride ... and 1 gram, the generic equivalent of Valtrex® by ... the 12 months ending December 31, 2010, according to ...
... 2011 NephRx Corporation today announced issuance of a ... factor peptide NX002 as a potential treatment for inflammatory ... have applications in acute and chronic diseases of the ... has been shown to stimulate the growth of epithelial ...
Cached Medicine Technology:Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2NephRx Corp. Awarded U.S. Patent for Use of Novel Growth Factor Peptide NX002 in Inflammatory Bowel Disease 2
(Date:9/30/2014)... leading cause of allergy-related sudden deaths in the U.S., ... to 2010, conducted by researchers at Montefiore ... Medicine of Yeshiva University . The study, published online ... Immunology , also found that the risk of fatal ... and African-Americans and that such deaths increased significantly in ...
(Date:9/30/2014)... EverStryke , the permanent match currently offered ... with a free book and class all about survival education ... an investigative review. , “Joe Marshall of SurvivalLife.com is ... preparation niche, and this product is an excellent way to ... products that Joe offers on his website to help people ...
(Date:9/30/2014)... 2014 The American Diabetes Association ... diabetics curb their sweet tooth, but the most recent ... September, suggests that zero-calorie sweeteners may actually be linked ... , The Weizmann Institute of Science in Israel ... to mice, the mice developed glucose intolerance. They then ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... 2014 A group of Americans is headed ... epidemic that, left unchecked, could create a catastrophic, global pandemic. ... to Africa. John Rogers, the Executive Director the Eugene Bell ... fight a disease most think mankind conquered long ago: tuberculosis. ... ago is on the comeback in several countries - what’s ...
Breaking Medicine News(10 mins):Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... Patricia A. Woertz Appointed to Board of Directors, ... & Gamble,Company (NYSE: PG ) today announced ... chief executive officer of Archer Daniels Midland,Corporation (NYSE: ... directors effective,immediately., (Photo: http://www.newscom.com/cgi-bin/prnh/20080108/CLTU115-a ), ...
... ... Expertise in Healthcare, BROOKFIELD, Wis., Jan. ... company, has added,Shakila Shimp as Director of Client Services for ... provider-side expertise,to the company,s health care industry customers., Shimp ...
... 43 million Americans,suffering from arthritis, hip replacement is ... traditional hip replacement, called hip,resurfacing, is on the ... minimized risk of dislocation and potential benefits related ... (See video from Stryker at:, http://media.medialink.com/WebNR.aspx?story=34296 ) ...
... and "Paperless" Environment ... Make it Among the First of Its Kind, DUBLIN, ... Hospital this morning at 7 a.m. sharp to begin caring ... Methodist, the first new, full-service hospital to be built in,central ...
... TMK ) will release Fourth Quarter 2007 earnings after ... with Torchmark,s,Fourth Quarter 2007 Earnings Release, you are invited ... live over the Internet on Thursday,February 7, 2008 at ... the,Company,s Q4-2007 earnings press release and other financial and,statistical ...
... Statin Use May Be Associated with Reduced Cancer Risk ... may be at lower risk for developing cancer, especially ... statins directly prevent cancer. , Laboratory studies have shown ... from observational studies has been inconsistent. , To ...
Cached Medicine News:Health News:Procter & Gamble Announces Appointment of Director 2Health News:Shimp Joins Pinstripe as Director of Client Services for Healthcare Group 2Health News:OhioHealth Opens Doors to Next Generation Hospital 2Health News:OhioHealth Opens Doors to Next Generation Hospital 3Health News:OhioHealth Opens Doors to Next Generation Hospital 4Health News:OhioHealth Opens Doors to Next Generation Hospital 5Health News:Torchmark Corporation Announces Fourth Quarter 2007 Earnings Release and Conference Call 2Health News:Other highlights in the Jan. 8 JNCI 2Health News:Other highlights in the Jan. 8 JNCI 3Health News:Other highlights in the Jan. 8 JNCI 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: